Quote Request
Genomic Sequencing for Pancreatic Cancer
At Alfa Cytology, we provide comprehensive research services with a strong focus on genomic sequencing for pancreatic cancer. Our advanced genomic sequencing platforms enable precise identification and characterization of genetic mutations, aiding in the early detection, treatment, and management of pancreatic cancer. Our services are designed to support researchers and pharmaceutical companies in developing more effective diagnostics and targeted therapies for this challenging disease.
Introduction to Genomic Sequencing for Pancreatic Cancer
Genomic sequencing has revolutionized cancer research, offering unprecedented insights into the genetic landscape of tumors. Pancreatic cancer, known for its poor prognosis and high mortality rate, often harbors a complex array of genetic alterations. These mutations play a crucial role in tumor initiation, progression, and resistance to therapy, making them critical targets for diagnostic and therapeutic strategies.
Fig. 1 ctDNA employed to identify targetable mutations (Adashek, J.J., et al., 2021)
Pancreatic cancer is frequently associated with mutations in key oncogenes and tumor suppressor genes, including KRAS, TP53, CDKN2A, and SMAD4. These mutations drive tumorigenesis and contribute to the disease's aggressive nature. Understanding the specific genetic alterations in a patient's tumor can guide personalized treatment approaches and inform prognosis.
| Mutations | Description |
| KRAS Mutations | Mutations in the KRAS gene are found in over 90% of PDAC cases. These mutations occur early in tumor development and play a key role in driving cell growth and proliferation. KRAS mutations are considered one of the most important genetic alterations in pancreatic cancer and have become a primary target for drug development and diagnostic testing. |
| TP53 Mutations | The tumor suppressor gene TP53 is frequently mutated in pancreatic cancer, leading to the loss of its function in controlling cell cycle arrest and apoptosis. These mutations contribute to the aggressiveness of the tumor and its resistance to therapies. |
| CDKN2A Mutations | The CDKN2A gene, which regulates cell cycle progression, is often deleted or inactivated in pancreatic cancer. Loss of CDKN2A function leads to uncontrolled cell division and tumor growth. |
| SMAD4 Mutations | Mutations in the SMAD4 gene, which is involved in the TGF-beta signaling pathway, are present in approximately 50% of PDAC cases. These mutations contribute to the cancer's ability to evade growth inhibitory signals and promote metastasis. |
| BRCA1/BRCA2 Mutations | Germline mutations in BRCA1 and BRCA2, commonly associated with breast and ovarian cancers, are also found in a subset of pancreatic cancer patients. These mutations impair DNA repair mechanisms, making tumors more sensitive to DNA-damaging agents such as platinum-based chemotherapy and PARP inhibitors. |
Our Services
At Alfa Cytology, we offer a range of genomic sequencing services tailored to the needs of pancreatic cancer research:
Provides a comprehensive analysis of the entire genome, identifying all genetic alterations present in the tumor. WGS is ideal for discovering novel mutations and understanding the full genetic landscape of pancreatic cancer.
Focuses on the exome, where most disease-related mutations occur. WES is a cost-effective option for identifying clinically relevant mutations and is widely used in cancer research.
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
Alfa Cytology is committed to advancing the understanding of pancreatic cancer through cutting-edge genomic sequencing technologies. Our expertise, state-of-the-art facilities, and dedication to precision ensure that you receive the highest quality data to drive your research forward. Partner with us to unlock the genetic secrets of pancreatic cancer and develop the next generation of diagnostic and therapeutic solutions. Contact us today to learn more about how our genomic sequencing services can support your research objectives.
References
- Li K, Tandurella JA, et al., Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. 2022 Nov 14;40(11):1374-1391.e7.
- Adashek, J.J.; Janku, F.; Kurzrock, R. Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. Cancers 2021, 13, 3600.
